An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low).
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.4175
Abstract: Importance Erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 [human epidermal growth factor receptor 2]) is an important prognostic and predictive factor in breast cancer. Anti-ERBB2 therapies have improved outcomes in ERBB2-positive breast cancer. However,… read more here.
Keywords: breast cancer; erbb2 low; cancer; receptor ... See more keywords
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.7476
Abstract: Key Points Question Do the demographics, clinicopathologic characteristics, and prognosis differ between breast cancers with no erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu) expression (ERBB2 negative) and those with low-level ERBB2 expression… read more here.
Keywords: low breast; breast cancer; clinicopathologic characteristics; erbb2 low ... See more keywords